logo
10 AI-Safe, Highest-Paying Jobs, Some With  Six-Figure Salaries

10 AI-Safe, Highest-Paying Jobs, Some With Six-Figure Salaries

Forbes10-07-2025
Many jobs are being replaced by AI, but many in-demand, high-paying jobs that don't require AI ... More skills are growing fast, paying as much as $150K annually.
According to Gallup, 22% of U.S. workers are worried they will lose their jobs to generative AI—a seven percent increase since 2021. Companies are moving faster than expected to replace positions, and many workers are seeking the in-demand roles AI has created to future-proof their jobs by 2030. But what about job seekers who are not AI-prepared or not looking for AI positions? If you're hunting for AI-safe, highest-paying jobs that are in demand and paying high salaries, you've come to the right place.
10 AI-Safe, Highest-Paying Jobs
Worried job seekers, unprepared for AI-required positions, are lost in the job market. Many are taking steps to outsmart AI by focusing on jobs AI can't do. Some have sought side hustles that don't require AI. And others are searching for roles AI won't replace. To help these job seekers, Resume Genius just released its 2025 Fastest-Growing, AI-Proof Jobs Report. Their analysis showcases the 10 fastest-growing and highest-paying jobs that AI won't replace.
'AI can write code and crunch numbers, but it can't comfort a patient or make a call in a crisis," says Eva Chan, career expert at Resume Genius. "The safest jobs right now are the most human ones. The fastest-growing work today depends on care, judgment and presence, which are all things AI still can't do.'
To identify these jobs, Resume Genius researchers used data from the U.S. Bureau of Labor Statistics to pinpoint 10 professions that are predicted to have a fast growth rate above 10% from 2023 to 2030. They calculated an automation risk below 50% using an automation risk probability calculator. Each jobs has a U.S. annual median salary of $49,500 or more.
The 10 professions that qualified for a top ten position meet the criteria posed by the researchers. Healthcare engineering fields dominate the list, offering high earning potential and long-term stability in a world impacted by AI. The list is ordered from highest-to-lowest salary, followed by estimated job growth and AI job takeover risk.
1. Computer and information research scientist ($149,910). 26% job growth, AI takeover risk: 31%. Master's degree required. The researchers state that, 'While AI tools can assist with data analysis and simulation, they can't replicate the human creativity and scientific reasoning needed to build entirely new systems.' The skills for this field are nearly impossible for AI to carry out because they require an understanding of theoretical computer science, original problem-solving and the ability to think abstractly.
2. Physician assistant ($133,260). 28% job growth, AI takeover risk: 0%. Master's degree required. The researchers cite McKinsey & Company, who explain that healthcare has the lowest overall potential for AI replacement because only 35% of a health care provider's time can be automated.
3. Nurse practitioner ($132,050). 40% job growth, AI takeover risk: o%. Master's degree required. Although AI can enhance patient care and data collection, the researchers point out that nurse practitioner jobs are AI-Proof because they must be able to solve complex problems, be creative and have strong interpersonal skills.
4. Veterinarian ($125,510). 19% job growth, AI takeover risk: seven percent. Doctorate or professional degree required. The researchers indicate that this profession is AI proof because veterinarians must have an extensive understanding of animal biology, sharp manual dexterity for surgery, along with interpersonal skills to communicate animal conditions to owners.
5. Medical and health services manager ($117,960). 29% job growth, AI takeover risk: 16%. Bachelor's degree required. Experts agree that these jobs can't be automated because AI isn't capable of the interpersonal skills, ethics and physical dexterity required.
6. Speech-language pathologist ($95,410). 18% job growth, AI takeover risk: nine percent. Master's degree required. According to experts, AI can't replicate the high degree of personal interaction and emotional intelligence to diagnose and tailor treatments to each patient's unique needs and circumstances.
7. Operations research analyst ($91,290). 23% job growth, AI takeover risk: 42%. Bachelor's degree required. 'AI might speed up calculations, but it can't replace the analyst's skill in understanding messy real-world problems or in using judgment to guide decisions,' the researchers conclude.
8. Epidemiologist ($83,980). 19% job growth, AI takeover risk: seven percent. Master's degree required. The researchers comment that studies show AI tools increase the power of epidemiological research, but these professionals require a level of human judgment and ethical consideration that AI can't replicate.
9. Logistician ($80,880). 19% job growth, AI takeover risk: 38%. Bachelor's degree required. Logisticians plan and manage how products move from one place to another. The researchers contend that, 'AI can support logistics by boosting efficiency, but logisticians are necessary for ethical decision‑making, making their role far more than a set of data‑driven tasks and resilient to automation.'
10. Wind turbine technician ($62,580). 60% job growth, AI takeover risk: 39%. Post-secondary non-degree award. Wind turbine technicians install, inspect and repair wind turbines—working at heights in all kinds of weather, experts say, but human technicians are still essential for climbing turbines, performing safety checks and handling urgent repairs that require hands-on skill and on-the-spot judgment calls.
Tips To Qualify For AI-Safe, Highest-Paying Jobs
Resume Genius career experts agree that AI will likely create more jobs than it eliminates. Yet, they emphasize that your ability to continuously adapt and develop new skills will be the key to success in the future job market. If you excel in creativity, emotional intelligence and problem-solving skills, the experts insist you'll always be in high demand because AI struggles to imitate soft skills like these.
The career experts believe it's important that you remember AI is your friend, not your enemy. They advocate using it as a tool to increase your productivity. 'AI can help automate repetitive tasks, allowing employees to focus on more complex and creative aspects of the job that require human judgment,' they assert. 'By familiarizing themselves with AI-powered tools rather than avoiding them, workers can ensure they remain competitive in the job market.'
Resume Genius experts advise that you monitor AI and tech-related advancements in your field by reading industry news and attending professional events to stay informed. They suggest that understanding these trends will help you anticipate changes and adapt your skill set accordingly. They encourage you to take courses or attend workshops that focus on emerging technologies and methodologies in your industry to stay ahead of your peers.
Chan believes that AI-safe, highest-paying jobs will flourish. 'Healthcare and science jobs will continue to grow,' she adds, 'Many of this year's top roles, like nurse practitioners, physician assistants and speech-language pathologists, rely on emotional intelligence, real-time decision-making and face-to-face interaction. These are skills AI isn't built to handle, and they're exactly what will keep people employed in an increasingly automated job market.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why Google should 'walk away' from Waymo
Why Google should 'walk away' from Waymo

Yahoo

time13 minutes ago

  • Yahoo

Why Google should 'walk away' from Waymo

Needham & Company senior media and internet analyst Laura Martin joins Market Domination with Josh Lipton to explain why Alphabet (GOOG, GOOGL) should ditch Waymo and focus on generative artificial intelligence (AI) instead. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Related videos The £70bn pension tax raid Reeves may not be able to resist 10 shares I wouldn't want to hold in a stock market crash After falling 16% in a day, this stock's on my list of shares to buy in August This FTSE 250 trust is easily beating the global index in 2025. Time to buy? Sign in to access your portfolio

EMCOR Group (EME) Sees EPS Surge as Net Income Climbs to US$241 Million
EMCOR Group (EME) Sees EPS Surge as Net Income Climbs to US$241 Million

Yahoo

time13 minutes ago

  • Yahoo

EMCOR Group (EME) Sees EPS Surge as Net Income Climbs to US$241 Million

EMCOR Group recently announced a regular quarterly cash dividend of $0.25 per common share, to be paid on July 31, 2025. This steady dividend approach aligns with the company's robust quarterly performance, which saw net income rise to $241 million and EPS increase substantially year-over-year. Additionally, the ongoing share buyback program has strengthened shareholder returns. Despite the broader market's moderate growth of 1.4% over the past week and 17% over the past year, EMCOR's notable share repurchases and solid financial outcomes appear to have amplified investor confidence, contributing to the company's impressive 55% stock price surge last quarter. We've spotted 1 risk for EMCOR Group you should be aware of. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. EMCOR Group's recent announcement of a quarterly dividend and the implementation of its share buyback program underline its commitment to enhancing shareholder returns. Despite a potential downside to the current share price of US$635.06, which exceeds the consensus analyst price target of US$549.57 by 13.46%, these actions could continue to buoy investor confidence. The company's performance over the past five years, with a total return exceeding 844.60%, showcases its robust long-term trajectory. In the last year, EMCOR's share performance exceeded both the broader market's 17.2% and the US Construction industry's 54.2% return, highlighting its strong standing relative to peers. The successful integration of acquisitions and strategic diversification into sectors like data centers and healthcare is anticipated to impact future revenue positively. This, coupled with operational efficiencies and strong revenue collaboration, may reinforce earnings projections. However, EMCOR's earnings forecasts of a 6.2% annual growth rate lag behind the broader market's 14.9% forecast, which could present challenges in meeting broader industry expectations. The company's impressive share price rise of 55% last quarter signals optimism, though its current value being above the target may indicate overvaluation concerns. Nevertheless, the consistent cash flow and healthy margins underscore its potential resilience against margin pressures, supply chain challenges, and other economic uncertainties. As analysts estimate revenue growth to 7.9% annually over the next three years, any tangible improvement in operational metrics could shift the valuation outlook positively. Unlock comprehensive insights into our analysis of EMCOR Group stock in this financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include EME. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY
Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY

Yahoo

time13 minutes ago

  • Yahoo

Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY

BioNTech SE and Pfizer recently received a positive recommendation from the European Medicines Agency for marketing authorization of their COVID-19 vaccine, which likely contributed to Pfizer's share price increase of 8% in the last quarter. The company's advancements in COVID-19 vaccine development, alongside other product-related announcements like the XTANDI and BRAFTOVI trial results, added weight to this upward movement. Despite legal challenges and declining earnings, Pfizer's focus on innovation and strategic partnerships like the one with XtalPi possibly countered broader market moves, which saw a smaller 1% increase in the same period. We've identified 3 warning signs for Pfizer that you should be aware of. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent positive recommendation from the European Medicines Agency for the COVID-19 vaccine developed by BioNTech SE and Pfizer has contributed to an 8% increase in Pfizer's share price over the last quarter. This news may provide a temporary boost to Pfizer's revenue and earnings forecasts, especially as the company continues to innovate amidst legal challenges and declining earnings. The authorization could enhance immediate market confidence in Pfizer's product pipeline, impacting future revenue projections positively. Over the past year, Pfizer experienced a total return of 13.78% including dividends, reflecting a challenging period for shareholders. When compared to the broader US market's return of 17.2% over the same period, Pfizer has underperformed, highlighting investor concerns over competitive pressures and revenue growth prospects. The current share price movement toward the analyst consensus price target of $29.23 suggests a cautiously optimistic outlook among some market participants. Analysts' revenue forecasts reflect potential declines due to increased competition for existing products, yet others anticipate that strategic shifts in research focus, especially in oncology, might mitigate future earnings risks. With a modest increase of 8% in shares largely tied to vaccine authorization, it underscores the uncertainty surrounding longer-term performance relative to bearish analyst expectations. Understand Pfizer's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store